Skip to main content

Bobo Donald E Jr's Form 4 filing

Edwards Lifesciences Corp (EW) · filed May 13, 2024

Accession no.
0001225208-24-005980
Filed
May 13, 2024
Trade date
May 10-11, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $439.1K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bobo Donald E JrCIK 0001196661Officer (CVP,Strategy/Corp Development)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 10, 2024Common StockMOption exerciseAcquired+5,000$45.28+$226,40052,749.72Direct
May 10, 2024Common StockSSaleDisposed−5,000$87.81F2−$439,05047,749.72Direct
May 11, 2024Common StockFTax withholdingDisposed−814$86.72−$70,590.0846,935.72Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 10, 2024Common StockMOption exerciseDisposed−5,000$0.00$065,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $87.415 to $88.050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Read the full filing on SEC EDGAR (opens in a new tab)